Gelonhui, April 19, 丨 Shoukang Group (0575.HK) announced on the 17th that its commercial strategic partner Jiangsu Wanbang Pharmaceutical has completed the third phase of the Senstend treatment of premature ejaculation in China. Jamie Gibson, CEO of Shoukang Group, indicated that Senstend is expected to help about 9 million patients in China in its first year of launch, and is expected to grow to over 170 million patients in the tenth year. The study achieved excellent results, reaching all four common main endpoints: the incubation time for vaginal ejaculation (“incubation time for vaginal ejaculation”), the premature ejaculation index (“premature ejaculation index”), ejaculation control, exponential satisfaction of premature ejaculation, and premature ejaculation index problems. Compared with baseline and placebo, Senstend performed significantly better clinically and statistically in terms of intravaginal ejaculation latency, ejaculation control and satisfaction, and reduced pain. Like the Group's previous studies in Europe and the US, Senstend was well tolerated by Chinese patients and partners, and no new side effects were reported. Jamie Gibson said he expects the group's commercial partners in China to submit new drug applications to the National Drug Administration at the end of the third quarter of 2023, and is expected to be approved 12 months later.